Aptose Biosciences Inc. 16,125,000 Common Shares (no par value per share) Underwriting AgreementUnderwriting Agreement • December 17th, 2019 • Aptose Biosciences Inc. • Biological products, (no disgnostic substances) • New York
Aptose Biosciences Inc., a company incorporated under the Canada Business Corporations Act (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 16,125,000 common shares, no par value per share (the “Shares”). The 16,125,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,418,750 Shares as provided in Section 2. The additional 2,418,750 Shares that may be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares, are collectively called the “Offered Shares.” Piper Jaffray & Co. (“Piper Jaffray”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent ther
